Cargando…
Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
[Figure: see text]
Autores principales: | Naderi-Azad, Sheida, Sickandar, Faisal, Pezo, Rossanna C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362262/ https://www.ncbi.nlm.nih.gov/pubmed/34409348 http://dx.doi.org/10.1016/j.jdin.2020.10.005 |
Ejemplares similares
-
Antiprogramed cell death‐1 therapy with microspheres for metastatic liver tumors
por: Kamimura, Hiroteru, et al.
Publicado: (2019) -
Anticytotoxic T-Lymphocyte Antigen-4 Induced Autoimmune Hypophysitis: A Case Report and Literature Review
por: Majchel, Deborah, et al.
Publicado: (2015) -
Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
por: Angrish, Manish D., et al.
Publicado: (2021) -
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
por: Jo, Hitomi, et al.
Publicado: (2023) -
The epistemic culture in an online citizen science project: Programs, antiprograms and epistemic subjects
por: Kasperowski, Dick, et al.
Publicado: (2018)